EVT-101

DB05956InvestigationalSmall molecule

Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease.

Mechanism: EVT 101 penetrates the brain at doses that are well tolerated in man and expected to be clinically relevant, shows activity in areas relevant to pain and, importantly, modulates the activity of specific brain regions during the performance of cognitive tasks relevant to Alzheimer's disease.
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease.Curator reviewed
Formula / weight: C₁₆H₁₅Cl₂F₃N₄ · 391.22 g/mol (avg)
Code names: EVT-101

Resolves to

Compound

Structure

InChIKeyOJBLXSPBJMGZDN-UHFFFAOYSA-NSMILESCl.Cl.CC1=NC=CN1CC1=CC(=CN=N1)C1=CC=C(F)C(=C1)C(F)F

Targets

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with EVT-101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.